C-Bridge Capital forms new biopharmaceutical company, AffaMed Therapeutics, which will collaborate with Samsung Bioepis to accelerate clinical development and registration of Samsung Bioepis’ next-gen...
The US Food and Drug Administration (FDA) has granted approval for Samsung Bioepis to use Ontruzant (trastuzumab-dttb) to treat a range of cancers.
Ontruzant, which will be marketed in the US by Me...
Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis, a joint venture established in 2012 by Samsung BioLogics and Biogen.
Biogen (USA) and Samsung Bioepis (South Korea) announced the European launch of IMRALDI (adalimumab), a biosimilar referencing HUMIRA. Starting today, IMRALDI will begin launching in major markets acr...
Biogen announced it has exercised its option to purchase additional shares of Samsung Bioepis Co., Ltd., a joint venture established in 2012 by Samsung BioLogics and Biogen.
AbbVie announced it reached a global resolution for all intellectual property-related litigation with the two companies regarding its biosimilar Imraldi (adalimumab).
Korean biopharmaceutical firm Samsung Bioepis informed that its biosimilar cancer drug Ontruzant has begun selling in Britain following approval from a European regulator (EMA).
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OK